Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572585 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00572585 is a Phase 2 study of Ulcerative Colitis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 60 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00572585, a Phase 2 study of Ulcerative Colitis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety and tolerability of AEB071 in the treatment of active, moderate to severe ulcerative colitis in patients who have failed conventional therapy using mesalamine or steroids
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AEB071
Study Locations (20)
Other
- Novartis Investigative Site - Aarhus
- Novartis Investigative Site - Odense C
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - Kiel
- Novartis Investigative Site - Leipzig
- Novartis Investigative Site - Lüneburg
- Novartis Investigative Site - Minden
- Novartis Investigative Site - Regensburg
- Novartis Investigative Site - Stuttgart
- Novartis Investigative Site - Krakow
- Novartis Investigative Site - Poznan
Michigan
- Novartis Investigative Site - Chesterfield Twp
- Novartis Investigative Site - Troy
Alabama
- Novartis Investigative Site - Mobile
Arizona
- Novartis Investigative Site - Mesa
Kansas
- Novartis Investigative Site - Topeka
Louisiana
- Novartis Investigative Site - Lafayette
Oklahoma
- Novartis Investigative Site - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572585
The ClinicalTrials.gov registry entry for NCT00572585 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00572585 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Michigan, Alabama.
Frequently Asked Questions
What is clinical trial NCT00572585 about?
NCT00572585 is a clinical study titled "Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis". This study will evaluate the efficacy, safety and tolerability of AEB071 in the treatment of active, moderate to severe ulcerative colitis in patients who have failed conventional therapy using mesalamine or steroids
What is the current status of trial NCT00572585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-04. Estimated completion is 2012-04.
What conditions does trial NCT00572585 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT00572585?
The interventions under investigation include: Placebo (DRUG), AEB071 (DRUG).
Who is sponsoring clinical trial NCT00572585?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572585 being conducted?
This trial has 20 study locations across Alabama, Arizona, Kansas, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.